|
US2013071403A1
|
|
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
US2011081686A1
|
|
Reactor for Bulk Manufacture of PCR Amplicons
|
|
US2009004203A1
|
|
Methods of treating measles infectious disease in mammals
|
|
US2009191227A1
|
|
Compositions and Methods for Enhancing Immune Responses to Vaccines
|
|
US2009209630A1
|
|
Gene delivery formulations and methods for treatment of ischemic conditions
|
|
CA2671540A1
|
|
Linear expression cassette vaccines
|
|
CA2658484A1
|
|
Compositions and methods for vaccinating against hsv-2
|
|
EP1804813A2
|
|
Formulations and methods for treatment of inflammatory diseases
|
|
WO2005116270A2
|
|
Influenza virus vaccine composition and method of use
|
|
CA2526128A1
|
|
Severe acute respiratory syndrome dna vaccine compositions and methods of use
|
|
CA2756797A1
|
|
Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
|
|
AU2003293196A1
|
|
Method for producing sterile polynucleotide based medicaments
|
|
EP1578193A2
|
|
Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
|
|
AU2003293042A1
|
|
Process for purification of plasmid dna
|
|
US2007105799A1
|
|
Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection
|
|
US2003186913A1
|
|
Expression of exogenous polynucleotide sequences in a vertebrate
|
|
US2003091544A1
|
|
Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
|
|
EP1278551A2
|
|
Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
|
|
WO0109303A2
|
|
Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
|
|
US6706694B1
|
|
Expression of exogenous polynucleotide sequences in a vertebrate
|
